comscoreTargeted Therapy

Targeted Therapy

192 Research news
 
 
Article
Lynparza Offers Benefits for Early-Stage HER2-Negative Breast Cancer With BRCA1/2 Mutation

Adding Lynparza to standard treatment for early-stage HER2-negative breast cancer with a high risk of recurrence in people with a BRCA1 or BRCA2 mutation improved disease-free survival.

 
Article
Ibrance-Faslodex Combo Continues To Improve Overall Survival in Advanced-Stage, Hormone-Receptor-Positive Breast Cancer

The latest results from the PALOMA-3 trial show that combining Ibrance and Faslodex continues to offer better overall survival than Faslodex alone.

 
Article
Adding Tukysa to Standard of Care Continues To Improve Survival in Advanced-Stage HER2-Positive Breast Cancer

Adding Tukysa to the standard of care of Herceptin and Xeloda continued to improve both progression-free and overall survival in people diagnosed with either metastatic or unresectable locally advanced HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.

 
Article
Trodelvy Improves Outcomes for Previously Treated Metastatic Triple-Negative Breast Cancer

Compared to standard chemotherapy, Trodelvy offered better outcomes for people diagnosed with previously treated metastatic triple-negative breast cancer.

 
Article
People Receiving Cancer Treatment Develop ‘Adequate’ Immune Response to Pfizer COVID-19 Vaccine

Nearly all the people in a clinical trial who were receiving systemic intravenous cancer treatment had an adequate immune response to the Pfizer-BioNTech COVID-19 vaccine.

 
Article
Herceptin Biosimilar Seems as Effective as Herceptin

A study suggests that a drug that is a biosimilar to Herceptin, called MYL-1401O, is as effective as Herceptin and has similar side effects.

Jan 3, 2017 | Diagnosis and Targeted Therapy
 
Article
FDA Approves Piqray to Treat Advanced-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer With PIK3CA Mutation

FDA approves Piqray in combination with Faslodex to treat metastatic and advanced-stage, hormone-receptor-positive, HER2-negative breast cancer with a PIK3CA mutation that has grown after hormonal therapy treatment in postmenopausal women and men.

 
Article
New Chemo Meds Improve Survival for Women With Advanced-Stage Disease

Newer chemotherapy medicines and regimens, as well as targeted therapy medicines, are helping women with advanced-stage breast cancer live longer.

 
Article
Adding Perjeta to Herceptin and Chemotherapy After Surgery Shows Benefits in Early-Stage HER2-Positive Breast Cancer

Updated results show adding Perjeta to Herceptin and chemotherapy after surgery for early-stage HER2-positive breast cancer continues to reduce the risk of recurrence and to slightly improve survival.

 
Article
Ibrance Approved to Treat Men With Advanced-Stage Hormone-Receptor-Positive Breast Cancer

The FDA has approved Ibrance to treat men diagnosed with advanced-stage hormone-receptor-positive, HER2-negative breast cancer.

 
Article
Kisqali-Faslodex Combo Continues To Improve Overall Survival in Advanced-Stage, Hormone-Receptor-Positive Breast Cancer in Postmenopausal Women

The latest results from the MONALEESA-3 study show that combining Kisqali plus Faslodex continues to offer better overall survival than Faslodex alone.

 
Article
Adding Tukysa to Standard Treatment Reduces Brain Lesion Growth Risk in HER2-Positive Metastatic Breast Cancer

For people with HER2-positive breast cancer that has spread to the brain, adding Tukysa to standard treatment improved survival and reduced the risk that the brain lesions would grow.

 
Article
Tykerb May Treat Herceptin-Resistant HER2-Positive Breast Cancer

Research on cells suggests that HER2-positive breast cancers resistant to Herceptin may respond to Tykerb.

 
Article
FDA Approves Talzenna to Treat Metastatic Breast Cancer in Women With BRCA Mutations

The FDA has approved Talzenna (chemical name: talazoparib) to treat locally advanced or metastatic HER2-negative breast cancer in women with an inherited BRCA1 or BRCA2 mutation.

 
Article
Is 9 Weeks of Herceptin as Good as 1 Year of Herceptin?

While 9 weeks of Herceptin was associated with fewer heart problems compared to 1 year of Herceptin, the difference in disease-free survival was small and the researchers said 1 year of Herceptin should remain the standard of care.

Oct 29, 2018 | Diagnosis and Targeted Therapy
 
Article
Injectable Herceptin Shows Promise

A study suggests that an injectable form of Herceptin works just as well as and is as safe as the standard IV form of Herceptin to treat HER2-positive, early-stage breast cancer before surgery.

 
Article
FDA Approves Herceptin Biosimilar Trazimera to Treat HER2-Positive Breast Cancer

On March 11, 2019, the FDA approved Trazimera (chemical name: trastuzumab-qyyp), a biosimilar for Herceptin, to treat people diagnosed with HER2-positive breast cancer.

Mar 18, 2019 | Diagnosis and Targeted Therapy
 
Article
Herceptin Approved in Europe to Treat Breast Cancer

Herceptin plus hormonal therapy for advanced breast cancer is approved in Europe.

May 3, 2007 | Diagnosis and Targeted Therapy
 
Article
If Cancer Stops Responding to Herceptin, It May Have Switched From HER2-Positive to HER2-Negative

A new study suggests that about one-third of HER-positive breast cancers that stop responding or don't respond completely to Herceptin do so because the cancers change from HER2-positive to HER2-negative during treatment.

 
Article
Experimental Targeted Therapy May Help Treat People With Advanced-Stage Cancer Due to Abnormal BRCA Gene

A study found that more than 25% of people with an abnormal BRCA1 or BRCA2 gene being treated for advanced-stage breast, ovarian, pancreatic, or prostate cancer got some benefit from olaparib, an experimental targeted therapy medicine.

 
Article
Herceptin Plus Taxol Seems to Reduce Recurrence Risk of Small HER2-Positive Cancers

A small, early study suggests that a combination of Herceptin and Taxol seemed to reduce the risk of recurrence of small HER2-positive breast cancers that hadn't spread to the lymph nodes.

 
Article
Experimental Tucatinib Improves Survival in Metastatic HER2-Positive Breast Cancer, May Be New Standard of Care

Adding experimental tucatinib to the standard of care of Herceptin and Xeloda improved both progression-free survival and overall survival in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.

 
Article
Chemo Plus Herceptin Can Put Metastatic, HER2-Positive Disease Into Remission

Some metastatic, HER2-positive breast cancers will respond to Herceptin for several years, suggesting that long-term remission is possible.

 
Article
Experts Say No to Avastin for Breast Cancer

An FDA expert panel recommended that Avastin not be used to treat advanced breast cancer. But doctors may still recommend the medicine depending on a woman's unique situation.

Dec 6, 2007 | Diagnosis and Targeted Therapy
Showing 24 of 192